-transparent.png){kind=logo}
BACKGROUND The distribution of bone metastases on a bone scan has not been duly considered when assessing the prognosis of metastatic prostate cancer. METHODS The medical records of 76 patients with newly diagnosed, untreated metastatic prostate cancer were reviewed. According to the distribution of bone metastases on the initial bone scan, we divided the patients into three groups: Group I (having bone metastases exclusively within the pelvis and the lumbar spine), Group II (having bone metastases exclusively outside these bones), and Group III (having bone metastases in both areas). RESULTS Among the responders to androgen deprivation, those in Group I survived significantly longer than did those in Groups II or III. Because the extent of the disease and the distribution of histologic differentiation in Groups I and II were similar, the results indicate that the presence of bone metastases outside the pelvis and the lumbar spine is predictive of short survival time. This prediction was not possible when the extent of disease (EOD) grading system was used. CONCLUSIONS The distribution of bone metastases on the initial bone scan should be considered as a variable for the prognostic stratification of patients with metastatic prostate cancer.
K Yamashita, and
K Denno, and
T Ueda, and
Y Komatsubara, and
T Kotake, and
M Usami, and
O Maeda, and
S Nakano, and
Y Hasegawa
September 2009,
Journal of the Egyptian National Cancer Institute,
K Yamashita, and
K Denno, and
T Ueda, and
Y Komatsubara, and
T Kotake, and
M Usami, and
O Maeda, and
S Nakano, and
Y Hasegawa
January 2009,
Prostate cancer and prostatic diseases,
K Yamashita, and
K Denno, and
T Ueda, and
Y Komatsubara, and
T Kotake, and
M Usami, and
O Maeda, and
S Nakano, and
Y Hasegawa
November 2018,
The oncologist,
K Yamashita, and
K Denno, and
T Ueda, and
Y Komatsubara, and
T Kotake, and
M Usami, and
O Maeda, and
S Nakano, and
Y Hasegawa
June 1994,
British journal of urology,
K Yamashita, and
K Denno, and
T Ueda, and
Y Komatsubara, and
T Kotake, and
M Usami, and
O Maeda, and
S Nakano, and
Y Hasegawa
August 1989,
The Journal of urology,
K Yamashita, and
K Denno, and
T Ueda, and
Y Komatsubara, and
T Kotake, and
M Usami, and
O Maeda, and
S Nakano, and
Y Hasegawa
January 2016,
Clinical Medicine Insights. Oncology,
K Yamashita, and
K Denno, and
T Ueda, and
Y Komatsubara, and
T Kotake, and
M Usami, and
O Maeda, and
S Nakano, and
Y Hasegawa
May 2012,
Asian journal of andrology,
K Yamashita, and
K Denno, and
T Ueda, and
Y Komatsubara, and
T Kotake, and
M Usami, and
O Maeda, and
S Nakano, and
Y Hasegawa
March 2019,
Anticancer research,
K Yamashita, and
K Denno, and
T Ueda, and
Y Komatsubara, and
T Kotake, and
M Usami, and
O Maeda, and
S Nakano, and
Y Hasegawa
December 2012,
Urology,
K Yamashita, and
K Denno, and
T Ueda, and
Y Komatsubara, and
T Kotake, and
M Usami, and
O Maeda, and
S Nakano, and
Y Hasegawa
July 2014,
Urologic oncology,
